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Bridging gapsThe neuronal ceroid lipofuscinoses, collectively called NCLs, are rare and fatal lysosomal storage diseases that
mainly affect children. Due to the fact that NCLs are both rare and heterogeneous (mutations in thirteen different
genes) signiﬁcant gaps exist in both preclinical and clinical research. Altogether, these gaps are major hurdles to
bring therapies to patients while the need for new therapies is urgent to help them and their families. To deﬁne
gaps and discuss solutions, a round table discussion involving teams and different stake holders took place during
the 14th International Conference on Neuronal Ceroid Lipofuscinoses (Batten Disease) in Cordóba, Argentina.
Topics covered by the teams and their leaders (in parentheses) included basic and translational research gaps
with regard to large animal models (I. Tammen, D.N. Palmer), human NCL pathology and access to human tissue
(J.D. Cooper, H.H. Goebel), rare NCLs (S. Hofman, I. Noher), links of NCLs to other diseases (F.M. Platt), gaps be-
tween clinic and clinical trials (H. Adams, A. Schulz), international collaborative efforts working towards a cure
(S.E. Mole, H. Band) perspectives on palliative care from patient organizations (M. Frazier, A. West), and issues
NCL researchers face when progressing to independent career in academia (M. Bond). Thoughts presented by
the team leaders include previously unpublished opinions and information on the lack of understanding of dis-
ease pathomechanisms, gene function, assays for drug discovery and target validation, natural history of disease,
and biomarkers for monitoring disease progression and treatment effects. This article is not intended to review
the NCL literature. It includes personal opinions of the authors and it provides the reader with a summary of
gaps discussed and solutions proposed by the teams. This article is part of a Special Issue entitled: Current Re-
search on the Neuronal Ceroid Lipofuscinoses (Batten Disease).
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Signiﬁcant gaps exist in research of the neuronal ceroid lipofuscinoses
(NCLs), often collectively referred to as Batten disease [1]. The NCLs are
caused by mutations in thirteen different genes (Mole and Cotman, this
issue) and are classiﬁed as lysosomal storage diseases (LSDs), a group
of over 50 rare inherited metabolic disorders that result from defects in
lysosomal function [2]. The incidence of NCLs varies from type-to-type
and from country-to-country [3]. Together, mutations in CLN1, CLN2,
and CLN3 account for the vast majority of NCL cases, those in CLN5,
CLN6, CLN7, and CLN8 for the vast majority of rare NCL cases, whileSD, lysosomal storage disease;
iculum; PoC, proof-of-concept;
sease; NPC, Niemann–Pick type
poral lobe degeneration; JNCL,
a in childhood; EEG, electroen-
esearch on theNeuronal Ceroidmutations in CLN4, CLN10, CLN11, CLN12, CLN13, and CLN14 account
for only a very small proportion of all NCL cases (http://www.ucl.ac.uk/
ncl/SummaryTableMay2015.htm, Mole and Cotman, this issue) [3]. Al-
though grouped as NCLs because of similarities in pathology and clinical
manifestations (Radke et al., this issue; Cooper et al., this issue), the
NCLs are caused by mutations in genes which proteins have thus far
shown little or no cross-talk at a molecular level (Cárcel-Trullols et al.,
this issue) [4]. It is therefore not evident how therapies developed for
one NCL formmay translate to another form. From a therapy perspective,
the NCLs caused by mutations in genes encoding soluble lysosomal en-
zymes (CLN1, CLN2, CLN10, and CLN13) are considered targets for en-
zyme replacement therapy (ERT) and gene therapy [5]. For CLN2, a
phase 1/2 ERT open-label dose-escalation study is ongoing in patients
with late-infantile neuronal ceroid lipofuscinosis (CLN2) disease, to
evaluate safety, tolerability, pharmacokinetics, and efﬁcacy of intra-
cerebroventricular delivered recombinant tripeptidyl peptidase I
(ClinicalTrials.gov Identiﬁer: NCT01907087). CLN2 gene delivery is also
under investigation (clinical trials.gov Identiﬁer: NCT01161576) [6].
There is hope that CLN5, which is not known to encode an enzymatic
function (Cárcel-Trullols et al., this issue), might also be deliverable via
gene therapy as suggested by preclinical results in CLN5-deﬁcient sheep
(Palmer et al., this issue). Finding therapeutic entry points for NCLs
caused by mutations in CLN3, CLN6, CLN7, and CLN8 is much more
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They seem located either mainly in the endoplasmic reticulum (ER),
like CLN6 and CLN8, and/or the endolysosomal compartments, like
CLN3 (Cárcel-Trullols et al., this issue) [4,7]. Therefore, research
gaps and hurdles in the translation of therapies to the clinic vary con-
siderably from one NCL form to another.
Nonetheless, there are gaps that are common to most of the NCLs,
such as the lack of an in-depth understanding of the natural history of
the disease [8], which is one of the prerequisites to successfully pave
the road to clinical trials. Currently, aside from CLN2 (ClinicalTrials.gov
Identiﬁer: NCT01907087), this knowledge seems still insufﬁcient for
most other NCL forms. The collaborative efforts that achieved this goal
for the CLN2 ERT trial underline the value of compiling in a single
database NCL patient natural history data available in different
countries, clinics, research institutions, and families. Efforts continue
to try and achieve this goal (http://www.dem-child.eu/index.php/
wp03-epidemiology-natural-history.html).
To bridge our knowledge gaps in understanding the function of
the wildtype CLN proteins (Cárcel-Trullols et al., this issue), a variety
of organism and cell models are being used and further developed
(Bond et al., this issue). Hopefully, these model systems will yield a
more in-depth understanding of the disease pathomechanisms
associated with different CLN disease genes and alleles. The results
may also open new avenues for therapy as understanding CLN func-
tion may unmask druggable pathways that can compensate for the
loss of CLN function. Results from thesemodels will hopefully also fa-
cilitate the development of biomarkers and surrogate markers to
monitor disease progression, and therapeutic effects of drugs in the
clinic. Gaps in understanding CLN function also hamper the develop-
ment of assays for drug discovery and target validation. The obstacles
are perhaps less of an issue for ERT or gene-based therapies aimed at
replacing a missing enzyme, but they seem more signiﬁcant when
trying to develop and test therapies for NCLs caused by mutations
in transmembrane proteins. For these NCLs, ERT-based scenarios
offer currently no solution, and also the outcomes of preclinical
gene therapy studies trying to supply the wildtype gene have so far
met with limited success (Hughes et al., this issue) [9]. More encour-
aging results have recently been obtained using human induced plu-
ripotent stem (iPS)-derived cellular models for CLN3 [10,11]. It is
hoped that iPS-based cellular and organoid models offer a new set
of translational models that can facilitate drug discovery. Perhaps,
they also offer alternatives to NCLmouse or large NCL animal models.
Large NCL animal models are available but only for some of the NCLs
[12], and have been instrumental to move a therapy forward to the
clinic [13,14]. Mouse models are widely used in NCL research but
they do not always mimic important pathophysiological aspects of
human disease. Efﬁcacy studies in mouse models can also be ham-
pered by insufﬁcient target engagement due to pharmacokinetic
properties of drugs in this species. This should not prevent us from
developing therapies thatmight help patients. Therefore, it is important
to continue the development of alternative preclinical test systems such
as human iPS-based models that can raise our conﬁdence to propose
and move new therapies forward to patients.
In summary, to push much-needed treatments to the clinic faster,
it is of utmost importance to understand the critical translation-
relevant research gaps for the NCLs and ﬁnd solutions to bridge
gaps. Funding alone is not enough to close the gaps, it also requires
collaboration between all stakeholders including academic and clin-
ical researchers, industry, patients, families, patient associations and
policymakers [15]. In a joint session with patient organizations and
researchers, eight teams presented their thoughts on gaps and po-
tential solutions for bridging them. Topics discussed included large
animal models, human NCL pathology and access to human tissue,
rare NCLs, links to other diseases, the gap between clinic and clinical
trials, working together towards a cure, palliative care, and a
scientist's perspective on NCL research and career opportunities.2. Large animal models (I. Tammen, D.N. Palmer)
The recent elegant work demonstrating efﬁcacy of ERT in CLN2-
deﬁcient dogs exempliﬁes how instrumental a large animal model can
be in the translation of therapies from bench-to-bedside [14]. Brain
size and complexity, lifespan, and the spectrum of clinical signs are all
arguments in favor of using large animalmodels in preclinical PoC stud-
ies. Downsides are costs, handling, ethical issues and often also the lack
of natural large animal mutants for certain NCLs including CLN3, for
which a genetically engineered CLN3 minipig model is in progress
(http://www.exemplargenetics.com/pipeline/). Ovine models for CLN5
and CLN6 are being used to validate gene therapy-based approaches
(Palmer et al., this issue). Other large animal models identiﬁed with
CLN mutations include CLN1 (dog), CLN5 (dog and cattle), CLN6
(dog), CLN8 (dog), CLN10 (sheep and dog), and CLN12 (dog) [12]. The
team discussed some of the difﬁculties encountered when trying to
identify novel natural occurring CLNmutants. One hurdle is that affect-
ed animals are often deceased or unavailable for breeding and research.
Other obstacles include costly autopsies, owners dislike the association
with breeds of genetically deﬁcient stock, dogs are pets, owners are
often largely unaware of a need for models, and funding available to
support the search and characterization of newmodels is scarce and dif-
ﬁcult to obtain. However, since sequencing costs are no longer a serious
barrier, the team suggested to raise more awareness amongst breeders
and veterinarians, and provide both with a list of expert pathologists
and geneticists they can consult. It was also suggested to invite veteri-
narians to future NCL meetings. At the same time it was felt that clearer
inclusion criteria are needed to deﬁne NCL, as novel candidate genes
will likely emerge.
3. Human NCL pathology and access to human tissue
(J.D. Cooper, H.H. Goebel).
Scientists perform treatments in disease models whereas the ulti-
mate goal is to treat human disease. For a variety of practical and ethical
reasons, one relies on cellular and animal models which are not always
as informative as one would like them to be. Every single model has its
strengths and weaknesses. The authors' opinion is that mouse models
that genocopy a human disease can be good mechanistic models, but
at the same time they frequently fail to phenocopy important patho-
physiological aspects of a human disease. Hence, great care needs to
be taken when interpreting ﬁndings in such models with regard to
their translatability to human. For the purpose of better understanding
disease onset, progression and testing therapies, large animals may
offer better options because they might better phenocopy a human dis-
ease. For this reason large animalmodels can add great value, for testing
therapies as well as for understanding disease processes. The team
emphasized the huge gaps that still exist in understanding the pre-
symptomatic phase, the onset, and the progression of human NCL
pathologies. Non-invasive techniques including ophthalmological
measurements, EEG and MRI are being used to try and close some of
these gaps (http://www.dem-child.eu/index.php/wp03-epidemiology-
natural-history.html) [16,17], as access to human tissue is difﬁcult.
The number of samples available is limited, most samples represent
end-stage disease, and studies were performed years back without
technologies and knowledge available today. To improve the situation,
the team suggested that a coherent process should be put in place for
systematic archiving of humanNCL tissues in a single database. This vir-
tual biobank should list ideally all samples available in an anonymous
fashion and indicate their location aswell as the key genetic and clinical
information. Access to the database should be ‘open source’ for the re-
search community and a streamlined approval process should be in
place to request samples for studies. Since tissue donations are not fre-
quent, it was also suggested to improve the tissue donation process. For
example, by emphasizing the tremendous value of tissue donations to
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paring them to handle the difﬁcult emotional aspects of this theme. It
was felt that human tissue is and remains an invaluable resource to bet-
ter understand the NCLs. It was recommended that a dedicated team
should follow up on this theme.
4. Rare forms of NCL (S. Hofman, I. Noher)
Most rare cases of NCL are collectively caused bymutations in CLN5,
CLN6, CLN7, or CLN8 while mutations in CLN10, CLN11, CLN12, CLN13,
and CLN14 are extremely rare (http://www.ucl.ac.uk/ncl/
SummaryTableMay2015.htm) [3]. Therapeutic routes using ERT and
gene therapy are currently being investigated for the more prevalent
forms CLN1 [18] and CLN2 [6,13,14] and this may help to pave the
road to therapy for some of the rarer NCL forms including CLN5. Other-
wise, the team seemed to agree that for the rare NCLs, the gaps in re-
search and the challenges facing clinical translation of therapies seem
similar to those for the frequent forms. These included, in particular,
the lack of a uniﬁed registry database and uniﬁed clinical rating scales.
5. Links to other diseases (F.M. Platt)
The NCLs are rare diseases and research into any rare disease can
greatly beneﬁt from overlaps found with molecular mechanisms and/
or therapeutic entry points discovered in other diseases. Especially
(but not only) if the latter are more frequent. Examples presented by
the team included overlaps identiﬁed between Parkinson's disease
(PD) and Gaucher disease, as well as overlaps between Niemann–Pick
type C (NPC), Tangier, Smith–Lemli–Opitz syndrome (SLOS) and
Tuberculosis [19]. These links have been discovered on the basis of
clinical observations and genetic screens (PD and Gaucher), or on the
basis of cellular phenotypes (NPC e.a.). The general consensus was
that ﬁnding links between NCLs and other diseases requires more in-
depth knowledge of CLN gene function and pathogenic mechanisms.
Adding on a few examples beyond those mentioned by the team: het-
erozygous and homozygous mutations in CLN11 are associated with
frontotemporal lobe degeneration (FTLD) and NCL, respectively [20],
autosomal recessivemutations in CLN12 are associated with Parkinson-
ism [21], and cathepsin D deﬁciency (CLN10) is associated with
α-synuclein accumulation as seen in idiopathic and familial forms of
PD [22]. For CLN3, mutations have recently been associated with au-
tophagic vacuolar myopathy [23]. Of particular interest are also non-
syndromicmutations in CLN genes associatedwith retinal disease in pa-
tients without NCL [24,25]. Such novel mutants will hopefully spur NCL
research, provide new ideas for therapy, and facilitate understanding
CLN-function and pathomechanisms.
6. Bridging gaps between clinic and clinical trials
(H. Adams, A. Schulz)
The team re-emphasized that in the early clinical phase, new drugs
and treatments have to meet the criteria including safety and tolerabil-
ity. In addition, preliminary evidence of what dose is needed for efﬁcacy
is a desirable goal at the earliest clinical stage. It was discussed that one
of the challenges in NCL research is how to best gather and use clinical
information, that can inform on primary and secondary outcomes, and
that can deﬁne outcomes that can realistically be targeted and achieved
in a clinical trial. This is particularly challenging in diseases like the NCLs
because trials can only be performed in low numbers of patients. Ques-
tions like trial design andhow to conduct a rigorous trial are immediate-
ly eminent as outcomes should point at truly transformative beneﬁts for
the patient. It was also emphasized that it is important to keep in mind
what is of prime importance to the patient. For example, in CLN3disease
loss of vision is typically the ﬁrst debilitating change patients face and it
greatly impacts their quality of life including social and learning capabil-
ities, usually well before other CLN3-associated cognitive disturbancesemerge. Therefore, the beneﬁts of early treatments that primarily
block or delay retinal degeneration should not be underestimated.
Ideally, clinical observations and data gathered should help guide
and deﬁne hypothesis-driven, meaningful clinical endpoints. The team
stressed that it is also important that clinical investigators and patients
have a common understanding of what is feasible and acceptable from
the patient's point of view. The number of patients participating in trials
will always be low but investigators and clinicians nonetheless face the
difﬁcult task to deﬁne proper inclusion/exclusion criteria for taking pa-
tients into a trial. Regarding the trial itself, there was a clear recommen-
dation for scenarios that combine excellent standard clinical care and
clinical research. Achieving this can be challenging because patients
participating in trials often come from geographically distant regions
whilemaintaining the highest standard of care during the trialmight re-
quire extended hospitalization andmonitoring by a local highly special-
ized team. It was also emphasized that once proof-of-concept in
patients has been achieved, challenges should not be underestimated
to expand and conﬁrm ﬁndings in a larger and perhaps clinically more
diverse patient population.
7. Working together towards a cure (S.E. Mole, H. Band)
The NCLs are rare (http://www.ucl.ac.uk/ncl/index.shtml) [3] and
altogether, theymake up for only a small number of all patients affected
by the thousands of rare genetic diseases known today (http://www.
orpha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alpha
betical_order.pdf). Taken together, rare diseases account for a signiﬁ-
cant proportion of patients suffering from chronic diseases and the asso-
ciated socio-economic burden (http://www.irdirc.org/). To improve
this situation, the International Rare Disease Consortium has a goal to
deliver 200 new therapies by the year 2020. It is hoped that these will
include also one or more NCLs. Within the European Union (EU) there
has been a long-standing focus to foster collaborative working models
in the rare disease ﬁeld. Special emphasis lies on collaborative working
models that are cross-sectional and include basic scientists in academia,
clinicians, biotechs and/or pharma, as well as patient organizations.
Endeavors in the NCL ﬁeld include the EU funded the DEM-CHILD
project (http://www.dem-child.eu/index.php/background-16.html)
which is coming to completion. Also, a new European collaborative con-
sortium (BATCure) has been assembled and a proposal submitted in the
context of the Horizon 2020 call PHC-14-2015.
8. Palliative care (M. Frazier, A. West)
The team gave the following interpretation of what palliative care
means to the Batten disease community: “a holistic, multi-disciplinary
approach that enables someone with an NCL diagnosis and their family
to live a life that is the best it can be”. A priory, this requires early diag-
nosis which in many countries is not state-of-the-art. Even in countries
where the diagnostic tools are available, it often takes years before a
proper diagnosis is established. Therefore, general awareness and fo-
cused educational programs targeting those that could facilitate early
diagnosis (e.g. ophthalmologists) are desirable and this strategy is ac-
tively pursued by NCL foundations. It wasmentioned that contributions
of families keep changing the landscape of supportive research and care.
Nonetheless, questions were raised how to further improve socio-
cultural, payment and access support for patients and their families. In
a broader context of neurodegenerative diseases, the question was
also asked how we can accelerate more holistic social science research
to improve care for children with such devastating diseases. Towards
this goal, one area the team identiﬁed for further development was to
better deﬁne and communicate in the global NCL community which
current assets are available. For example, with respect to best practice
in palliative care (including initial family engagement), day-to-day
care, communication, hospice provision, and end-of-life care. Support
organizations including the Batten Disease Support and Research
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seem ideally positioned to foster further progress in these areas.
9. Junior scientist's perspective on NCL research and career
(M. Bond)
Many junior NCL scientists, after ﬁnishing their PhD or a postdoc in
the NCL ﬁeld, eventually move on to other areas of research. Rewards,
career and funding opportunities are greater in larger and popular re-
search ﬁelds covered bymany laboratories and provide junior scientists
with more options, ﬂexibility and continuity in their research careers.
Many of the difﬁculties postdocs and junior scientists face on their
way to establish an independent career in academia have recently
been summarized [26]. To help researchers continue in the NCL ﬁeld,
it was felt that transition grants might be one way to help scientists
bridge this critical phase in their career. The wish was also expressed
to improve sharing of knowledge and tools in the NCL community.
Some also felt that new students might be attracted to NCL research
by making available a comprehensive educational data package that
covers basic research and clinical data.
In conclusion, to successfully bring therapies to the patients we need
to bridge existing gaps in NCL research and a short list of recommenda-
tions proposed at this meeting is shown below. Bridging gaps is best ac-
complished by fostering and embracing collaborative interdisciplinary
efforts involving all stake holders. Raising more general awareness
and providing educational programs should further support these ef-
forts to facilitate early diagnosis, family planning, and improve palliative
care and treatment.
Short list of recommendations
• Raise awareness amongst veterinarians and breeders of the great
value of large animal models, and help them to identify new models
by providing a list of expert pathologists and geneticists for consulta-
tion.
• Establish an “open source” virtual biobank listing ideally all world-
wide available NCL tissue samples, and improve the tissue donation
process.
• Merge available patient registries in a single database, and unify
registry standards and rating scale standards.
• Identify clinically meaningful measures and outcomes.
• Try to establish links between NCLs and other diseases.
• Provide educational programs to ophthalmologists and medical
doctors to facilitate early diagnosis.
• Communicate in global NCL community the assets available to help
patients and their families.
• Foster funding scenarios for young researchers enabling them to
progress and pursue independent careers in NCL research.
• Foster and embrace collaborative interdisciplinary efforts involving all
stake holders.
Transparency document
The Transparency document associated with this article can be
found, in the online version.
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